Cure My Disease

Don't miss your cure!

 Log in / Sign up

Three-Drug cocktail aims to shrink breast tumors before surgery

NCT ID NCT07691333

Not yet recruiting Disease control Sponsor: Fujian Cancer Hospital Source: ClinicalTrials.gov ↗

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This study tests whether a combination of three drugs—kumorixilib, capecitabine, and letrozole—given before surgery can slow or shrink tumors in people with HR-positive, HER2-negative breast cancer. Participants take the drugs for six 28-day cycles, then have surgery. The main goal is to measure changes in a tumor growth marker called Ki-67 after one cycle. The study is small, with 35 participants, and is designed to explore safety and early signs of effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
kumorixilib, capecitabine, and letrozole
What this could lead to
If successful, this combination could shrink tumors before surgery, potentially improving outcomes for people with HR+/HER2- breast cancer.
What could go wrong
This is a small, early-phase study with only 35 participants, so results may not apply to everyone. Side effects from the three drugs could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST NEOPLASMS HR+/HER2- BREAST CANCER

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fujian Cancer Hospital

    Fuzhou, Fujian, 350001, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Fujian Provincial Hospital

    Fuzhou, Fujian, 350001, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The Second Affiliated Hospital of Fujian Medical University

    Quanzhou, Fujian, 362000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.